A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

NCT05873907 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Graft-versus-host Disease (cGVHD)

Interventions

DRUG: AMG 592
OTHER: Placebo

Sponsor

Amgen